InsiderTrades.com logo
Johanne Kaplan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Johanne Kaplan Biography and Net Worth

Chief Development Officer of Promis Neurosciences

Johanne Kaplan is a former VP of Research at Sanofi Genzyme. Over the course of her 23-year career at Genzyme, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, cancer immunotherapy and autoimmunity. Most recently, as VP of Neuroimmunology Research, Dr. Kaplan led the contribution of the Genzyme science team supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an Immunotoxicology program. Her work has resulted in over 70 scientific publications and multiple patents. Dr. Kaplan holds a PhD in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York, USA.

What is Johanne Kaplan's net worth?

The estimated net worth of Johanne Kaplan is at least $60.53 thousand as of February 19th, 2026. Dr. Kaplan owns 3,941 shares of Promis Neurosciences stock worth more than $60,534 as of August 25th. This net worth estimate does not reflect any other investments that Dr. Kaplan may own. Learn More about Johanne Kaplan's net worth.

How do I contact Johanne Kaplan?

The corporate mailing address for Dr. Kaplan and other Promis Neurosciences executives is 1920 Yonge Street Suite 200, Toronto A6, M4S 3E2. Promis Neurosciences can also be reached via phone at (416) 847-6898 and via email at [email protected]. Learn More on Johanne Kaplan's contact information.

Has Johanne Kaplan been buying or selling shares of Promis Neurosciences?

Johanne Kaplan has not been actively trading shares of Promis Neurosciences within the last three months. Most recently, on Thursday, February 19th, Johanne Kaplan bought 1,629 shares of Promis Neurosciences stock. The stock was acquired at an average cost of $15.35 per share, with a total value of $25,005.15. Following the completion of the transaction, the insider now directly owns 3,941 shares of the company's stock, valued at $60,494.35. Learn More on Johanne Kaplan's trading history.

Who are Promis Neurosciences' active insiders?

Promis Neurosciences' insider roster includes Johanne Kaplan (Chief Development Officer), and Eugene Williams (Chairman and Co-Founder). Learn More on Promis Neurosciences' active insiders.

Are insiders buying or selling shares of Promis Neurosciences?

In the last twelve months, Promis Neurosciences insiders bought shares 6 times. They purchased a total of 710,585 shares worth more than $8,655,727.23. The most recent insider tranaction occured on April, 22nd when Director Patrick D Kirwin bought 4,000 shares worth more than $45,320.00. Insiders at Promis Neurosciences own 1.5% of the company. Learn More about insider trades at Promis Neurosciences.

Information on this page was last updated on 4/22/2026.

Johanne Kaplan Insider Trading History at Promis Neurosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/19/2026Buy1,629$15.35$25,005.153,941View SEC Filing Icon  
See Full Table

Johanne Kaplan Buying and Selling Activity at Promis Neurosciences

This chart shows Johanne Kaplan's buying and selling at Promis Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Promis Neurosciences Company Overview

Promis Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $15.36
Low: $14.50
High: $15.36

50 Day Range

MA: $13.31
Low: $10.16
High: $15.19

2 Week Range

Now: $15.36
Low: $6.27
High: $27.40

Volume

60,642 shs

Average Volume

106,621 shs

Market Capitalization

$137.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A